MedTrace Logo

Study of BB-025, Alone and After BB-031, in Healthy Volunteers

NCT07202663 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-04-06

No results posted yet for this study

Summary

The goal of this 2-part clinical trial is to learn about the safety and pharmacokinetics (PK) of a single dose of BB-025 when given on its own and after being given BB-031. Researchers will compare BB-025 to placebo (a look-alike substance that contains no drug) both on its own and after being given a single dose of BB-031 to assess the use of BB-025 as a reversal agent.

In the first part of the study, participants will receive a single dose of BB-025 or placebo. They will be followed for 28 days to check if they have any symptoms.

In the second part of the study, participants will receive a single dose of BB-031 and then be given either BB-025 or placebo. These participants will also be followed for 28 days to check if they have any symptoms.

Conditions

  • Pharmacodynamics
  • Pharmacokinetics
  • Healthy Volunteers

Interventions

DRUG

BB-025

Reversal agent for BB-031

DRUG

BB-031

RNA aptamer

Sponsors & Collaborators

  • Basking Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Chris Argent, MD · Scientia Clinical Research Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-05
Primary Completion
2026-03-18
Completion
2026-03-18

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07202663 on ClinicalTrials.gov